Talphera, Inc. (TLPH)
NASDAQ: TLPH · Real-Time Price · USD
0.9285
-0.0515 (-5.26%)
Sep 16, 2025, 1:40 PM EDT - Market open

Company Description

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.

The company’s lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates.

The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024.

The company was incorporated in 2005 and is based in San Mateo, California.

Talphera, Inc.
Talphera logo
CountryUnited States
Founded2005
IPO DateFeb 14, 2011
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees13
CEOVincent Angotti

Contact Details

Address:
1850 Gateway Drive, Suite 175
San Mateo, California 94404
United States
Phone650 216 3500
Websitetalphera.com

Stock Details

Ticker SymbolTLPH
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001427925
ISIN NumberUS00444T2096
Employer ID41-2193603
SIC Code2834

Key Executives

NamePosition
Vincent J. AngottiChief Executive Officer and Director
Raffi Mark AsadorianChief Financial Officer
Anil N. DasuChief Engineering Officer
Dr. Shakil Aslam M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Sep 15, 2025DNotice of Exempt Offering of Securities
Sep 12, 2025SCHEDULE 13DFiling
Sep 12, 2025SCHEDULE 13GFiling
Sep 10, 20258-KCurrent Report
Sep 9, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2025DEF 14AOther definitive proxy statements
Aug 29, 2025PRE 14AOther preliminary proxy statements
Aug 14, 202510-QQuarterly Report
Aug 14, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report